Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. — CFSMEATLAS
Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria.
This study tested whether taking natural anti-inflammatory supplements (glutamine, N-acetyl cysteine, and zinc) along with a special diet could help ME/CFS patients whose intestines had become too permeable ("leaky gut"). Researchers measured immune markers in the blood before and after 10-14 months of treatment and found that 24 out of 41 patients improved significantly, with the best results in younger patients and those with shorter illness duration.
Why It Matters
This study provides preliminary evidence that intestinal barrier dysfunction (leaky gut) may be a treatable mechanism in ME/CFS and suggests a potential therapeutic target. The finding that symptom improvement correlates with normalization of specific immune markers offers a measurable outcome that could guide future treatment development and patient monitoring.
Observed Findings
Serum IgA and IgM responses to LPS from gram-negative bacteria were significantly reduced after 10-14 months of NAIOS treatment
Fifty-eight percent (24/41) of patients showed clinical improvement or remission after treatment
Younger patient age and shorter disease duration (<5 years) were associated with better clinical response
Attenuation of IgA and IgM responses to translocated LPS predicted clinical improvement
Clinical improvements were measured using the Fibromyalgia and Chronic Fatigue Syndrome Rating Scale
Inferred Conclusions
Normalization of intestinal permeability and related immune responses to bacterial LPS may be associated with clinical recovery in ME/CFS
Natural anti-inflammatory and antioxidative supplements combined with dietary modification may reduce gut-derived systemic inflammation in some CFS patients
Leaky gut represents a novel and potentially modifiable pathway in CFS pathogenesis
Clinical prognosis in CFS may be related to age of onset and disease duration, with younger, more recently affected patients showing better treatment response
Remaining Questions
What is the mechanism by which these specific supplements restore intestinal barrier function?
What This Study Does Not Prove
This study does not prove that leaky gut causes ME/CFS—it only shows an association. The lack of a control group and placebo arm means we cannot determine how much improvement was due to the treatment versus natural variation, regression to the mean, or placebo effect. The small sample size and single-arm design limit generalizability.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →